Clinical treatment regimens for chronic heart failure: a review

REFERENCES

• REMME WJ, SWEDBERG K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. (2001) 22(17):1527–1560. ••Excellent overall guide to all aspects ofCHF.
   Google Scholar
• Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J. Card. Fail. (1999) 5(4):357–382. ••Explains neurohormonal theory of CHFparticularly well.
   Google Scholar
• KRUM H: Guidelines for management of patients with chronic heart failure in Australia. Med. J. Aust. (2001) 174(9):459–466.
   PubMed Web of Science ®Google Scholar
• KELLY DT: Paul Dudley White International Lecture. Our future society. A global challenge. Circulation (1997) 95(11):2459–2464.
   Google Scholar
• HUNT SA, BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). I Am. Coll. Cardiol (2001) 38(7):2101–2113. ••Similar to [1].
   Google Scholar
• KOSTIS JB, DAVIS BR, CUTLER J et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. "AMA (1997) 278(3):212–216.
   Google Scholar
• NAUGHTON MT: Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Thorax (1998) 53\(Suppl. 3):537–540.
   Google Scholar
• McALISTER FA, LAWSON FM, TEO KK, ARMSTRONG PW: A systematic review of randomized trials of disease management programs in heart failure. Am. J. Med. (2001) 110(5):378–384.
   PubMed Web of Science ®Google Scholar
• COHN JN: The management of chronic heart failure. N Engl. J. Med. (1996) 335(7):490–498.
   PubMed Web of Science ®Google Scholar
• COHN JN, ARCHIBALD DG, ZIESCHES et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl. I Med. (1986) 314(24):1547–1552.
   Google Scholar
• MILLER RR,AWAN NA, MAXWELL KS, MASON DT: Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl. J. Med. (1977) 297(6):303–307.
   PubMedGoogle Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl. I Med. (1991) 325(21):1468–1475. •Important negative trial.
   Google Scholar
• PACKER M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol (1992) 20(1):248–254. ••Excellent review discussing bothhaemodynarnic and neurohormonal thoery of CHE
   Google Scholar
• GHEORGHIADE M, CODY RJ, FRANCIS GS, MCKENNA WJ, YOUNG JB, BONOW RO: Current medical therapy for advanced heart failure. Heart Lung (2000) 29(1):16–32.
   PubMedGoogle Scholar
• KOSTUK WJ: Congestive heart failure: what can we offer our patients? Can. Med. Assoc. J. (2001) 165(8):1053–1055.
   PubMedGoogle Scholar
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl. I Med. (1991) 325(5):293–302. ••Landmark trial establishing ACEI asbeneficial in CHE
   Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl. I Med. (1987) 316(23):1429–1435. ••Second landmark trial establishing ACEIusage in CHE
   Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl. I Med. (1992) 327(10):669–677.
   Google Scholar
• Important trial establishing ACEI benefit in CHF patients without symptoms. YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. I Med. (2000) 342(3):145–153. Important trial showing benefits for ACEI usage in patients at risk of ischaemic heart disease and CHE
   Google Scholar
• PACKER M, POOLE-WILSON PA, ARMSTRONG PW et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 100(23):2312–2318. •Important trial to establish ACEI dose.
   Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al:Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349(9054):747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582–1587. •Important negative trial to follow up ELITE I.
   Google Scholar
• TSUYUKI RT, YUSUF S, ROULEAU JL et al.: Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and p-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can. I Cardiol (1997) 13(12):1166–1174.
   PubMedGoogle Scholar
• COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. I Med. (2001) 345(23):1667–1675.
   PubMed Web of Science ®Google Scholar
• SWEDBERG K, PFEFFER M, GRANGER C et al.: Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. I Card. Fail. (1999) 5(3):276–282.
   PubMedGoogle Scholar
• KAYE DM, LEFKOVITS J, JENNINGS GL, BERGIN P, BROUGHTON A, ESLER MD: Adverse consequences of high sympathetic nervous activity in the failing human heart. I Am. Coll Cardiol. (1995) 26(5):1257–1263. Important study showing sympathetic activation in CHF as deleterious.
   Google Scholar
• SWEDBERG K, HJALMARSON A, WAAGSTEIN F, WALLENTIN I: Prolongation of survival in congestive cardiomyopathy by 3-receptor blockade. Lancet (1979) 1(8131):1374–1376. •Interesting early data on 0-Blocker benefits in CHE
   Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl. I Med. (1996) 334(21):1349–1355. ••Important trial establishing benefits forcarvedilol usage in CHE
   Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001–2007. ••Important trial establishing benefit for0-blockade in CHE
   Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl. I Med. (2001). 344(22):1651–1658. •Trial showing benefit for carvedilol in severe CHE
   Google Scholar
• CHANNER KS, MCLEAN KA, LAWSON-MATTHEW P, RICHARDSON M: Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br. Heart I. (1994) 71(2):146–150.
   PubMedGoogle Scholar
• VARGO DL, KRAMER WG, BLACK PK, SMITH WB, SERPAS T, BRATER DC: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. (1995) 57(6):601–609.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. J. Med. (1999) 341(10):709–717. ••Landmark trial showing benefit forspironolactone usage in CHE
   Google Scholar
• The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl. I Med. (1997) 336(8):525–533. •Important trial to show digoxin has no mortality benefit in CHE
   Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl. J. Med. (1991) 325(5):303–310. ••Important trial in that it showed benefitfor neurohormonal antagonism over just improving haemodynarnics on disease progression.
   Google Scholar
• COHN JN, ZIESCHE S, SMITH R et al.: Effect of the calcium antagonist felodipine as Supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation (1997) 96(3):856–863.
   Google Scholar
• PACKER M, O'CONNOR CM, GHALI JK et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl. J. Med. (1996) 335(15):1107–1114.
   Google Scholar
• THACKRAY S, WITTE K, CLARK AL, CLELAND JG: Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur. J. Heart Fail. (2000) 2(2):209–212.
   PubMed Web of Science ®Google Scholar
• A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) investigators. N Engl. I Med. (1997) 337(22):1576–1583.
   PubMedGoogle Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. (1994) 154(13):1449–1457.
   PubMedGoogle Scholar
• SINGH SN, FLETCHER RD, FISHER SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl. I Med. (1995) 333(2):77–82.
   Google Scholar
• DOVAL HC, NUL DR, GRANCELLI HO, PERRONE SV, BORTMAN GR, CURIEL R: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet (1994) 344(8921):493–498.
   Google Scholar
• MANDI Y, FARKAS G, OCSOVSZKY I, NAGY Z: Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Res. Exp. Med. (lier) (1995) 195(5):297–307.
   PubMedGoogle Scholar
• BURGER MR, BURGER AJ: BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential. Carr. Opin. Investig. Drugs (2001) 2(7):929–935.
   PubMedGoogle Scholar
• CLELAND JG, MCGOWAN J: Levosimendan: a new era for inodilator therapy for heart failure? Curt: Opin. Cardiol (2002) 17(3):257–265.
   Google Scholar
• TEERLINK JR: Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): Approaching the asymptote of efficacy?" Card. Fail. (2002) 8(3):124–127.
   Google Scholar
• CAZEAU S, RITTER P, LAZARUS A et al.: Multisite pacing for end-stage heart failure: early experience. Pacing Clin. Electrophysiol. (1996) 19(11, Pt 2):1748–1757.
   Google Scholar
• AURICCHIO A, STELLBRINK C, BLOCK M et al.: Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation (1999) 99(23):2993–3001.
   Google Scholar
• LECLERCQ C, KASS DA: Retiming the failing heart: principles and current clinical status of cardiac resynchronization. I Am. Coll. Cardiol (2002) 39(2):194–201. ••Excellent review of the current data oncardiac resynchronisation therapy.
   Google Scholar
• CAZEAU S, LECLERCQ C, LAVERGNE T et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl. I Med. (2001) 344(12):873–880. ••Clinical trial showing haemodynarnicbenefit for biventricular pacing.
   Google Scholar
• ABRAHAM WT, FISHER WG, SMITH AL et al.: Cardiac resynchronization in chronic heart failure. N Engl. I Med. (2002) 346(24):1845–1853. •Clinical trial showing mortality and morbidity benefits to 6 months with biventricular pacing.
   Google Scholar
• MOSS AJ, HALL WJ, CANNOM DS et al.: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic 1575 Defibrillator Implantation Trial Investigators. N Engl. J. Med. (1996) 335(26):1933–1940. •Trial showed benefit for internal cardiac defibrillators in patients post infarct with positive electrophysiological studies for ventricular tachycardia.
   Google Scholar
• BUXTON AE, LEE KL, FISHER JD, JOSEPHSON ME, PRYSTOWSKY EN, HAFLEY G: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl. I Med. (1999) 341(25):1882–1890.
   PubMed Web of Science ®Google Scholar
• MOSS AJ, ZAREBA W, HALL WJ et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl. Med. (2002) 346(12):877–883. ••Landmark trial showing benefit forinternal cardiac defibrillators in patients with LVEF 30% post MI without a prior event.
   Google Scholar
• KLEIN H, AURICCHIO A, REEKS, GELLER C: New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am. J. Cardiol. (1999) 83(5B):91D–97D.
   Google Scholar